Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have earned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $22.83.

Several research analysts have recently issued reports on the company. Royal Bank of Canada restated an “outperform” rating and issued a $29.00 price target on shares of Neumora Therapeutics in a research report on Wednesday, September 4th. Needham & Company LLC restated a “buy” rating and set a $23.00 price objective on shares of Neumora Therapeutics in a report on Friday. HC Wainwright initiated coverage on shares of Neumora Therapeutics in a report on Tuesday, October 1st. They issued a “buy” rating and a $30.00 target price on the stock. Finally, Mizuho initiated coverage on shares of Neumora Therapeutics in a report on Monday, July 8th. They issued an “outperform” rating and a $20.00 price target for the company.

Neumora Therapeutics Stock Performance

Shares of NMRA opened at $16.49 on Friday. The company has a market cap of $2.63 billion and a price-to-earnings ratio of -6.44. The stock has a fifty day moving average price of $12.73 and a two-hundred day moving average price of $11.36. Neumora Therapeutics has a 52-week low of $8.33 and a 52-week high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.37) earnings per share for the quarter, hitting the consensus estimate of ($0.37). As a group, research analysts predict that Neumora Therapeutics will post -1.48 EPS for the current fiscal year.

Insider Activity at Neumora Therapeutics

In other Neumora Therapeutics news, CFO Joshua Pinto sold 31,642 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $11.78, for a total transaction of $372,742.76. Following the completion of the transaction, the chief financial officer now owns 154,658 shares in the company, valued at approximately $1,821,871.24. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Robert A. Lenz sold 30,788 shares of the stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $11.81, for a total transaction of $363,606.28. Following the completion of the transaction, the insider now owns 339,205 shares in the company, valued at approximately $4,006,011.05. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Joshua Pinto sold 31,642 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $11.78, for a total transaction of $372,742.76. Following the completion of the transaction, the chief financial officer now directly owns 154,658 shares of the company’s stock, valued at approximately $1,821,871.24. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 110,538 shares of company stock valued at $1,390,513. 26.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Neumora Therapeutics

A number of large investors have recently modified their holdings of NMRA. Artal Group S.A. raised its stake in shares of Neumora Therapeutics by 14.5% during the 1st quarter. Artal Group S.A. now owns 2,924,052 shares of the company’s stock worth $40,206,000 after purchasing an additional 371,350 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in Neumora Therapeutics during the first quarter worth approximately $10,354,000. Callan Capital LLC boosted its stake in Neumora Therapeutics by 222.6% in the 2nd quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock valued at $6,500,000 after purchasing an additional 456,207 shares during the period. Baker BROS. Advisors LP bought a new stake in shares of Neumora Therapeutics in the first quarter valued at about $8,715,000. Finally, Bank of New York Mellon Corp boosted its holdings in Neumora Therapeutics by 474.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 235,593 shares of the company’s stock valued at $2,316,000 after purchasing an additional 194,559 shares during the period. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.